Antibody dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab

Elotuzumab, a recently approved antibody for the treatment of multiple myeloma (MM), has been shown to stimulate Fcγ receptor (FcγR)-mediated antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells towards myeloma cells. The modulatory effects of elotuzumab on other effector cel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Kurdi, Ahmed T., Glavey, Siobhan V., Bezman, Natalie A., Jhatakia, Amy, Guerriero, Jennifer L., Manier, Salomon, Moschetta, Michele, Mishima, Yuji, Roccaro, Aldo, Detappe, Alexandre, Liu, Chia-Jen, Sacco, Antonio, Huynh, Daisy, Tai, Yu-Tzu, Robbins, Michael D., Azzi, Jamil, Ghobrial, Irene M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6030488/
https://ncbi.nlm.nih.gov/pubmed/29654064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0998
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados